Biodesix (BDSX) to Release Earnings on Wednesday

Biodesix (NASDAQ:BDSX) is expected to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Biodesix to announce earnings of ($0.86) per share and revenue of $26.0260 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.32. Biodesix had a negative return on equity of 2,101.40% and a negative net margin of 33.26%.The firm had revenue of $25.55 million during the quarter, compared to analysts’ expectations of $23.12 million. On average, analysts expect Biodesix to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Biodesix Stock Performance

Biodesix stock opened at $21.20 on Monday. The company has a market cap of $219.55 million, a PE ratio of -5.22 and a beta of 0.53. The company has a current ratio of 2.82, a quick ratio of 2.82 and a debt-to-equity ratio of 5.09. Biodesix has a 1 year low of $5.26 and a 1 year high of $24.92. The company’s 50-day moving average is $18.93 and its two-hundred day moving average is $15.25.

Analysts Set New Price Targets

BDSX has been the subject of a number of recent research reports. Roth Capital started coverage on shares of Biodesix in a research note on Wednesday, June 24th. They set a “buy” rating and a $32.00 price target for the company. HC Wainwright assumed coverage on shares of Biodesix in a report on Monday, June 15th. They set a “buy” rating and a $26.00 target price for the company. Canaccord Genuity Group upped their target price on shares of Biodesix from $22.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Finally, Weiss Ratings raised Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 12th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Biodesix currently has an average rating of “Moderate Buy” and a consensus target price of $28.33.

Hedge Funds Weigh In On Biodesix

Several institutional investors and hedge funds have recently modified their holdings of BDSX. XTX Topco Ltd increased its position in shares of Biodesix by 99.4% during the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after acquiring an additional 102,494 shares in the last quarter. Millennium Management LLC acquired a new position in Biodesix in the 3rd quarter worth $113,000. Geode Capital Management LLC boosted its stake in Biodesix by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after purchasing an additional 2,235 shares during the period. DRW Securities LLC bought a new position in Biodesix during the 4th quarter worth about $105,000. Finally, State Street Corp increased its holdings in Biodesix by 15.6% during the 4th quarter. State Street Corp now owns 17,802 shares of the company’s stock worth $121,000 after purchasing an additional 2,400 shares in the last quarter. 20.96% of the stock is currently owned by institutional investors and hedge funds.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.